Eli Lilly Obesity Drug Mounjaro Beats Legacy Trulicity On Cardio-Renal Health

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to Trulicity (dulaglutide), a GLP-1 receptor agonist.

In SURPASS-CVOT, Mounjaro achieved the primary objective by demonstrating a non-inferior rate of major adverse cardiovascular events (MACE-3), including cardiovascular death, heart attack, or stroke, versus Trulicity.

In addition, while not controlled for multiplicity-adjusted type-1 error, Mounjaro showed improvements on key measures of A1C, weight, renal function, and all-cause mortality.

Also Read: What’s Going On With Eli Lilly Stock On Tuesday?

The trial, which enrolled more than 13,000 participants and lasted more than four and a half years, is the largest and longest study of tirzepatide to date, the company said in a ...